BEST UNLIMITED TURBO LONG CERTIFICATE - ELI LILLY & CO | Market Closed - Euronext Paris 12:30:01 2024-05-15 pm EDT | ||
| 21.17 EUR | +4.69% |
|
| Current month | -0.76% | ||
| 1 month | +2.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-15 | 21.17 | +4.69% |
| 24-05-14 | 20.22 | -0.02% |
| 24-05-13 | 20.23 | -2.36% |
| 24-05-10 | 20.72 | -1.94% |
| 24-05-09 | 21.13 | -0.86% |
Real-time Euronext Paris
Last update May 15, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| BV24S | |
| ISIN | DE000SQ3DD28 |
| Date issued | 2022-10-25 |
| Strike | 320.6 $ |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | 3.28 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.47 € |
|---|---|
| Lowest since issue | 1.109 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
764
USD
Average target price
850.4
USD
Spread / Average Target
+11.31%
- Stock Market
- Certificates
- BV24S Certificat
